Skip to content

Travere Therapeutics, Inc. TVTX Payments to Acquire Intangible Assets

Payments to Acquire Intangible Assets at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
BridgeBio Pharma logo
BridgeBio PharmaBBIO
PTC Therapeutics logo
PTC TherapeuticsPTCT
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.2B+72.3%

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s payments to acquire intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s payments to acquire intangible assets?
Travere Therapeutics, Inc. (TVTX) reported payments to acquire intangible assets of $22.18M in Q1 2026.
How has Travere Therapeutics, Inc.'s payments to acquire intangible assets changed year-over-year?
Travere Therapeutics, Inc.'s payments to acquire intangible assets increased by 88.2% year-over-year, from $11.78M to $22.18M.
What is the long-term trend for Travere Therapeutics, Inc.'s payments to acquire intangible assets?
Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s payments to acquire intangible assets has grown at a 32.2% compound annual growth rate (CAGR), from $19.05M to $58.16M.